Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite

Primary Outcome Measures:

• Identification of potential drug targets for therapeutic strategies to treat asbestos fiber-related diseases [ Time Frame: At time of analysis ] [ Designated as safety issue: No ]

Detailed Description:

OBJECTIVES:

• Identify patients with known asbestos exposure at early stages of disease development (i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural mesothelioma).
• Determine the expression levels of tumor-associated proteins in these patients.
• Analyze samples of serum and pleural effusions obtained from these patients.
• Determine the proteomic profile of samples obtained from these patients.
• Determine the molecular mechanisms associated with the regulation of the extracellular matrix microenvironment proteins (e.g., osteonectin, intelectin, or matrix metalloproteins) involved in disease onset and progression.

OUTLINE:

This is a multicenter study.

Patients undergo collection of body cavity fluid, including pleural effusion, and blood. Specimens, including fresh frozen malignant pleural mesothelioma tumor tissue, if available, are analyzed for proteomic profile, gene expression profile, and tumor-associated protein expression levels.

PROJECTED ACCRUAL:

A total of 200 patients will be accrued for this study.

Eligibility Criteria

DISEASE CHARACTERISTICS:

• Exposure to vermiculite or asbestos insulation
  • Symptomatic or nonsymptomatic exposure-related disease
• Seen at a clinic in Libby, Montana (CARD Clinic) or Michigan (COEM)

PATIENT CHARACTERISTICS:

• Not specified

PRIOR CONCURRENT THERAPY:

• Not specified